


=> d l1
 L1 HAS NO ANSWERS
 L1 STR



O⁻¹Ak
 G1 H, Ak
 G2 G1, X, CN, [@1]
 G3 G2, OH

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 10:30:19 ON 14 JAN 2004)

FILE 'REGISTRY' ENTERED AT 10:30:34 ON 14 JAN 2004


L1 STRUCTURE UPLOADED
 L2 38 S L1
 L3 1 S OXAZOLE/CN
 L4 47040 S 16.239.9/RID
 L5 38 S L1 SAM SUB=L4
 L6 720 S L1 FULL SUB=L4
 L7 713 S L6 AND CAPLUS/LC
 L8 7 S L6 NOT L7
 L9 0 S L8 AND CAOLD/LC

FILE 'CAPLUS' ENTERED AT 10:35:40 ON 14 JAN 2004

L10 6 S L6

L10 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:314682 CAPLUS
 DOCUMENT NUMBER: 132:334449
 TITLE: Preparation of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of IMPDH enzyme
 INVENTOR(S): Gu, Henry H.; Dhar, T. G. Murali; Iwanowicz, Edwin
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-------------------|-----------------|------------|
| WO 2000026197 | A1 | 20000511 | WO 1999-US24889 | 19991022 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1127054 | A1 | 20010829 | EP 1999-960145 | 19991022 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002528533 | T2 | 20020903 | JP 2000-579586 | 19991022 |
| US 6624184 | B1 | 20030923 | US 1999-427953 | 19991027 |
| PRIORITY APPLN. INFO.: | | | US 1998-106180P | P 19981029 |
| | | | WO 1999-US24889 | W 19991022 |
| OTHER SOURCE(S): | | MARPAT 132:334449 | | |
| GI | | | | |



AB The title compds. ZJKLX [I; Z = (un)substituted monocyclic or bicyclic ring system contg. up to 4 heteroatoms selected from N, O, and S; J = NR7, CO; K = NR7, CO, CHR9; L = a single bond, CO, CR10R11, etc.; X = alkyl, alkenyl, cycloalkylalkyl, etc.; R7 = H, alkyl, alkenyl, etc.; R9 = H, alkyl, alkenyl, etc.; R10, R11 = H, F, Cl, etc.], useful in treating or preventing IMPDH assocd. disorders, such as transplant rejection and autoimmune disease, were prepd. E.g., a multi-step synthesis of glycineamide II was given. Compds. I are effective at 0.1-500 mg/kg/day.


IT 267405-39-0P 267405-40-3P 267405-41-4P

267405-42-5P 267405-43-6P 267405-44-7P
 267405-45-8P 267405-46-9P 267405-47-0P
 267405-48-1P 267405-49-2P 267405-50-5P
 267405-51-6P 267405-52-7P 267405-53-8P
 267405-54-9P 267405-55-0P 267405-56-1P
 267405-57-2P 267405-58-3P 267405-59-4P
 267405-60-7P 267405-61-8P 267405-62-9P
 267405-63-0P 267405-64-1P 267405-65-2P
 267405-66-3P 267405-67-4P 267405-68-5P
 267405-69-6P 267405-70-9P 267405-71-0P
 267405-72-1P 267405-73-2P 267405-74-3P
 267405-75-4P 267405-76-5P 267405-77-6P
 267405-78-7P 267405-79-8P 267405-80-1P
 267405-81-2P 267405-82-3P 267405-83-4P
 267405-84-5P 267405-85-6P 267405-86-7P
 267405-87-8P 267405-88-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of IMPDH enzyme)


RN 267405-39-0 CAPLUS

CN Ethanediamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 267405-40-3 CAPLUS

CN Ethanediamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 267405-41-4 CAPLUS

CN Ethanediameide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(3-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 267405-42-5 CAPLUS


CN Ethanediameide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 267405-43-6 CAPLUS


CN Carbamic acid, [[3-[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267405-44-7 CAPLUS

CN Ethanediamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 267405-45-8 CAPLUS

CN Ethanediame, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(phenylmethyl)- (9CI)
(CA INDEX NAME)




RN 267405-46-9 CAPLUS

CN Ethanediame, N-(4-cyanophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 267405-47-0 CAPLUS

CN Ethanediame, N-(1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-(9CI) (CA INDEX NAME)




RN 267405-48-1 CAPLUS

CN Ethanediame, N-[1,1-bis(hydroxymethyl)propyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-(9CI) (CA INDEX NAME)




RN 267405-49-2 CAPLUS

CN Ethanediame, N-(2-hydroxy-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-50-5 CAPLUS

CN Alanine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 267405-51-6 CAPLUS

CN Ethanediame, N-(2-hydroxy-1,1-dimethylpentyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-52-7 CAPLUS

CN Ethanediame, N-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-53-8 CAPLUS

CN Ethanediame, N-[2-(dimethylamino)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-54-9 CAPLUS

CN Ethanediame, N-(1,1-diethyl-2-propynyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-55-0 CAPLUS

CN Ethanediame, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(1,1,3,3-tetramethylbutyl)-(9CI) (CA INDEX NAME)



RN 267405-56-1 CAPLUS


CN Ethanediame, N-(1,1-dimethylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-(9CI) (CA INDEX NAME)



RN 267405-57-2 CAPLUS

CN Ethanediame, N-[1-(hydroxymethyl)cyclopentyl]-N'-[3-methoxy-4-(5-


oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-58-3 CAPLUS

CN Ethanediame, N-[2-(4-fluorophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 267405-59-4 CAPLUS
 CN Tyrosine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-.alpha.-methyl-,
 methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 267405-60-7 CAPLUS
 CN Tryptophan, N-[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-.alpha.-
 methyl-, methyl ester (9CI) (CA INDEX NAME)






RN 267405-61-8 CAPLUS

CN Ethanediame, N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-62-9 CAPLUS

CN Ethanediame, N-(1,1-dimethyl-3-oxobutyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-63-0 CAPLUS

CN Ethanediame, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(1-methyl-1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 267405-64-1 CAPLUS

CN Ethanediame, N-(2-hydroxy-1,2-dimethyl-1-phenylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-65-2 CAPLUS

CN Alanine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 267405-66-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 267405-67-4 CAPLUS


CN Ethanediamide, N-(1-ethynylcyclohexyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-(9CI) (CA INDEX NAME)



RN 267405-68-5 CAPLUS


CN Ethanediamide, N-[(1R)-1-(hydroxymethyl)-1-methylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267405-69-6 CAPLUS


CN Alanine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl- (9CI)
(CA INDEX NAME)




RN 267405-70-9 CAPLUS

CN Ethanediame, N-[1,1-dimethyl-2-oxo-2-(1-piperidinyl)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 267405-72-1 CAPLUS
 CN Ethanediame, N-[1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 267405-73-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methylalanyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 267405-74-3 CAPLUS

CN Ethanediame, N-[2-[3-(acetylmethylamino)-1-pyrrolidinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267405-75-4 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N,2-dimethyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 267405-76-5 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 267405-77-6 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 267405-78-7 CAPLUS
 CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 267405-79-8 CAPLUS
 CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 267405-80-1 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N-[2-(1H-imidazol-4-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 267405-81-2 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N-[2-(acetylamino)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 267405-82-3 CAPLUS


CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N-[2-(1H-imidazol-1-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 267405-83-4 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 267405-84-5 CAPLUS


CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)






RN 267405-85-6 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N-(2-methoxyethyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 267405-86-7 CAPLUS


CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 267405-87-8 CAPLUS

CN Ethanediamide, N-[2-[4-(2-methoxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 267405-88-9 CAPLUS
 CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT